Kamada Ltd's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Kamada Ltd (KMDA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Kamada Ltd vs Its Competitors
- TTM: Trailing 12-month revenue of 180M vs 179,112M combined for its competitors (0.1% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (-1.0% annualized vs trailing 12 months), vs decelerating (-4.0%) for its tracked peer group.
- Growth: Kamada Ltd generated 14.5% revenue growth year over year in Q4 2025, vs 0.6% for its competitors combined.
- Profitability: Its 8.0% net margin compares with 8.9% for the peer group.
- Scale: Kamada Ltd ranks #195 of 545 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Kamada Ltd accounted for 0.1% of combined revenue among its tracked peer group, up from 0.1% a year earlier.
- Peer differentiation: Revenue per employee of $0.46M compares with $1.00M for the peer group (0.5x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
KMDA Sales vs. its Competitors, Q4 2025
Kamada Ltd reported revenue growth of 14.54 % year on year in Q4 2025, above its competitors' combined revenue growth of 0.56 %.
With a net margin of 7.97 %, Kamada Ltd reported lower profitability than its competitors (8.94 %).
Kamada Ltd generated 0.10 % of the combined sales of its peer group, up from 0.09 % a year earlier.
API endpoints for this dataset
Kamada Ltd vs. its Competitors, Q4 2025
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Kamada Ltd reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Kamada Ltd and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Kamada Ltd | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (3) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (7) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Kamada Ltd's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 14.5% for Kamada Ltd. Kamada Ltd's share of combined industry revenue moved from 0.01% to 0.01%, a gain of 0.00 percentage points.
Kamada Ltd's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Kamada Ltd | Yes | Yes | Yes | No |
| Competitors combined (51) | ||||
| High-Confidence Competitors (5) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 87.50 % (7 of 8) | 100.00 % (8 of 8) | 75.00 % (6 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
KMDA Stock Performance relative to its Competitors
KMDA Stock Performance relative to High-Confidence Competitors
KMDA Stock Performance relative to Similar-Size Competitors
KMDA Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Prelude Therapeutics Inc | 282.9% | Outperformed |
| 2 | Amicus Therapeutics inc | 282.9% | Outperformed |
| 3 | Viatris Inc | 282.9% | Outperformed |
| 4 | Teva Pharmaceutical Industries Limited | 282.9% | Outperformed |
| 5 | Amneal Pharmaceuticals Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Kamada Ltd's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Kamada Ltd's Comment on Competition and Industry Peers
Publicly Traded Peers of Kamada Ltd
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Kamada Ltd |
421.84 | 180.46 |
 Beone Medicines Ltd |
612,622.08 | 6,128.24 |
 Amgen Inc |
250,468.48 | 38,095.00 |
 Vertex Pharmaceuticals Inc |
139,617.37 | 12,951.60 |
 Bristol myers Squibb Company |
127,573.42 | 50,033.00 |
 Regeneron Pharmaceuticals Inc |
95,499.36 | 16,896.20 |
| SUBTOTAL | 1,357,892.79 | 179,299.37 |
Sign in to see all competitors of Kamada Ltd .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Kamada Ltd versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Kamada Ltd's Competitors Named by the Company
Competitive relationships identified from Kamada Ltd reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Takeda | Company report | 85% |
| Kedrion | Company report | 85% |
| CSL Behring | Company report | 85% |
| Talecris Biotherapeutics, Inc. | Company report | 85% |
| ADMA Biologics Inc. | Company report | 85% |
| Octapharma | Company report | 85% |
| Grifols S.A. | Company report | 85% |
| Biotest AG | Company report | 85% |
| Peak Bio Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Kamada Ltd's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Kamada Ltd's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Teva Pharmaceutical Industries Limited | United States 42.55 % |
| Viatris Inc | Developed Markets 59.34 % |
| Biomarin Pharmaceutical Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Kamada Ltd's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Kamada Ltd | 422 | 459,186 | 51,394 |
| Beone Medicines Ltd | 612,622 | 510,686 | 54,642 |
| Amgen Inc | 250,468 | 2,930,385 | 672,538 |
| Vertex Pharmaceuticals Inc | 139,617 | 31,979,259 | 9,817,037 |
| Bristol myers Squibb Company | 127,573 | 1,539,477 | 284,338 |
| Regeneron Pharmaceuticals Inc | 95,499 | 1,096,444 | 312,615 |
| PEERS TOTAL | 1,357,471 | 1,001,084 | 136,766 |
Kamada Ltd's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Beone Medicines Ltd | United States 54.39 % |
| Vertex Pharmaceuticals Inc | United States 63.04 % |
| Bristol myers Squibb Company | United States 69.43 % |
| Teva Pharmaceutical Industries Limited | Europe 30.49 % |
| Aquestive Therapeutics Inc | United States 60.98 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Kamada Ltd's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Kamada Ltd's industry classification, broader than the peer set above. Market cap in millions of $.Kamada Ltd ranks #195 of 495 companies by market capitalization in its industry, holding 0.01 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 875, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,210,070 | 20.69 % |
| 2 | Johnson and Johnson | 674,004 | 11.53 % |
| 3 | Beone Medicines Ltd | 612,622 | 10.48 % |
| 4 | Abbvie Inc | 515,910 | 8.82 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 195 | Kamada Ltd | 422 | 0.01 % |
Market cap and industry share for the rest of Kamada Ltd's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-06.
Kamada Ltd's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 190 | Canton Strategic Holdings Inc | 447 | -50.88 % |
| 191 | Benitec Biopharma Inc | 444 | -44.93 % |
| 192 | Phathom Pharmaceuticals Inc | 440 | -61.03 % |
| 193 | Relmada Therapeutics Inc | 438 | 50.20 % |
| 194 | Puma Biotechnology Inc | 1,234 | 12.3% |
| 195 | Kamada Ltd | 422 | 2.89 % |
| 196 | Arvinas Inc | 1,234 | 12.3% |
| 197 | Prothena Corporation Public Limited Company | 1,234 | 12.3% |
| 198 | Rezolute Inc | 1,234 | 12.3% |
| 199 | Oculis Holding Ag | 1,234 | 12.3% |
| 200 | Altimmune inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Kamada Ltd's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-06. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Kamada Ltd's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (444 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 42.34 % | 37.89 % (avg) | +4.5 pp |
| Operating Margin | 14.54 % | industry median | +9.4 pp |
| EBITDA Margin | 13.00 % | -6.23 % (avg) | +19.2 pp |
| Capital Intensity (Capex / Revenue) | 0.00 % | 7.58 % (avg) | -7.6 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Kamada Ltd's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 19.8x | 26.6x | -6.8x |
| EV / EBITDA | 15.7x | 15.9x | -0.2x |
| P/B | 1.5x | 4.3x | -2.8x |
| Return on Equity | 7.51 % | industry aggregate | -12.61 % |
| Return on Invested Capital | 4.72 % | -9.83 % (avg) | 14.55 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Kamada Ltd's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue Growth | 10.19 % | 12.93 % | 12.12 % |
| Operating Margin | 7.06 % | 12.46 % | 14.54 % |
| Return on Invested Capital | 2.07 % | 3.68 % | 4.72 % |
| P/E | 33.6x | 22.9x | 19.8x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Kamada Ltd's Strategic Group Map
Kamada Ltd is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Kamada Ltd's trailing-12-month revenue growth of 12.1% and operating margin of 14.5% compares with an average of 11.8% growth and 11.8% margin across its 8 closest peers by combined growth, margin and ROIC -- Kamada Ltd sits above that peer average on growth and above it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Kamada Ltd's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Kamada Ltd falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Kamada Ltd's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 875 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 7.58 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Kamada Ltd's dedicated Suppliers and Customers pages, not here.
Kamada Ltd's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Kamada Ltd falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Kamada Ltd's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 9.4 points above the industry median.
Weaknesses
- Return on equity 12.6 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
- Trades at a lower P/E than the industry average (19.8x vs 26.6x) despite a higher return on invested capital -- a possible re-rating opportunity.
- A meaningful share of competitors (48.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-4.0% annualized).
Methodology: see Methodology: SWOT Analysis.
Kamada Ltd's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Kamada Ltd | 1.59 | 4.07 | 0.15 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Vertex Pharmaceuticals Inc | 1.30 | 2.83 | 0.06 |
| Bristol myers Squibb Company | 0.48 | 1.44 | 2.12 |
| Regeneron Pharmaceuticals Inc | 0.58 | 3.56 | 0.06 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Kamada Ltd's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Kamada Ltd | Q4 2025 | +12.1 % | +39.7 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +11.8 % | -39.6 % |
| Bristol myers Squibb Company | Q3 2026 | +6.9 % | -1.5 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +36.3 % | +33.5 % |
| PEERS TOTAL | +10.8 % | +2.4 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Kamada Ltd's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Kamada Ltd | Q4 2025 | +14.4 % | - |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +26.8 % | -4.4 % |
| Bristol myers Squibb Company | Q3 2026 | +20.7 % | +7.5 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +104.1 % | +49.1 % |
Kamada Ltd's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Kamada Ltd | 5.33% | 7.05% | 7.51% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Vertex Pharmaceuticals Inc | 14.16% | 16.63% | 20.08% |
| Bristol myers Squibb Company | 10.47% | 13.59% | 43.83% |
| Regeneron Pharmaceuticals Inc | 11.50% | 13.00% | 15.07% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Kamada Ltd's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Kamada Ltd | 20.66 | 2.34 |
| Beone Medicines Ltd | 924.91 | 99.97 |
| Amgen Inc | 28.60 | 6.57 |
| Vertex Pharmaceuticals Inc | 35.27 | 10.78 |
| Bristol myers Squibb Company | 13.77 | 2.55 |
| Regeneron Pharmaceuticals Inc | 20.00 | 5.65 |
| PEERS AVERAGE | 55.44 | 7.57 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.